Altered brainstem responses to modafinil in schizophrenia: implications for adjunctive treatment of cognition

[1]  D. Chapman.  New Evidence , 2011, Journal of human lactation : official journal of International Lactation Consultant Association.

[2]  Michael F. Green,et al.  The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? , 2011, Schizophrenia bulletin.

[3]  Daniel C. Javitt,et al.  A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia , 2011, Biological Psychiatry.

[4]  P. Blier,et al.  Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons. , 2011, The international journal of neuropsychopharmacology.

[5]  S. Lawrie,et al.  Midbrain activation during Pavlovian conditioning and delusional symptoms in schizophrenia. , 2010, Archives of general psychiatry.

[6]  T. Robbins,et al.  The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. , 2009, Annual review of neuroscience.

[7]  N. Volkow,et al.  Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. , 2009, JAMA.

[8]  Andrew J. Watrous,et al.  Modafinil Shifts Human Locus Coeruleus to Low-Tonic, High-Phasic Activity During Functional MRI , 2008, Science.

[9]  D. Durstewitz,et al.  The Dual-State Theory of Prefrontal Cortex Dopamine Function with Relevance to Catechol-O-Methyltransferase Genotypes and Schizophrenia , 2008, Biological Psychiatry.

[10]  J. Gold,et al.  Initial phase 2 trial of a nicotinic agonist in schizophrenia. , 2008, The American journal of psychiatry.

[11]  M. Minzenberg,et al.  Modafinil: A Review of Neurochemical Actions and Effects on Cognition , 2008, Neuropsychopharmacology.

[12]  E T Bullmore,et al.  Substantia nigra/ventral tegmental reward prediction error disruption in psychosis , 2008, Molecular Psychiatry.

[13]  E T Bullmore,et al.  How dopamine dysregulation leads to psychotic symptoms? Abnormal mesolimbic and mesostriatal prediction error signalling in psychosis , 2008, Molecular Psychiatry.

[14]  D. Javitt,et al.  The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. , 2007, The American journal of psychiatry.

[15]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[16]  D. Durstewitz,et al.  The ability of the mesocortical dopamine system to operate in distinct temporal modes , 2007, Psychopharmacology.

[17]  G. Dawe,et al.  Effects of short-term and chronic olanzapine treatment on immediate early gene protein and tyrosine hydroxylase immunoreactivity in the rat locus coeruleus and medial prefrontal cortex , 2006, Neuroscience.

[18]  T. Spencer,et al.  Modafinil Occupies Dopamine and Norepinephrine Transporters in Vivo and Modulates the Transporters and Trace Amine Activity in Vitro , 2006, Journal of Pharmacology and Experimental Therapeutics.

[19]  Johannes Schwarz,et al.  Psychosis pathways converge via D2High dopamine receptors , 2006, Synapse.

[20]  Philip D. Harvey,et al.  Cognition in schizophrenia: impairments, determinants, and functional importance. , 2005, The Psychiatric clinics of North America.

[21]  Bruce H. Littman,et al.  The ultimate model organism: progress in experimental medicine , 2005, Nature Reviews Drug Discovery.

[22]  Jonathan D. Cohen,et al.  An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. , 2005, Annual review of neuroscience.

[23]  I. Wilkinson,et al.  Modafinil modulates anterior cingulate function in chronic schizophrenia. , 2005, The British journal of psychiatry : the journal of mental science.

[24]  M. Seager,et al.  Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder , 2005, Psychopharmacology.

[25]  D. Weinberger,et al.  Genes, dopamine and cortical signal-to-noise ratio in schizophrenia , 2004, Trends in Neurosciences.

[26]  Luke Clark,et al.  Modafinil Improves Cognition and Attentional Set Shifting in Patients with Chronic Schizophrenia , 2004, Neuropsychopharmacology.

[27]  Philip Holmes,et al.  The Influence of Spike Rate and Stimulus Duration on Noradrenergic Neurons , 2004, Journal of Computational Neuroscience.

[28]  G. Ramakers,et al.  Modulation of cellular activity and synaptic transmission in the ventral tegmental area. , 2003, European journal of pharmacology.

[29]  S. Sesack,et al.  Anatomical Substrates for Glutamate‐Dopamine Interactions , 2003 .

[30]  J. Gold,et al.  Another view of therapy for cognition in schizophrenia , 2002, Biological Psychiatry.

[31]  A. Meyer-Lindenberg,et al.  Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia , 2002, Nature Neuroscience.

[32]  T. Sharp,et al.  Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity , 2001, Biological Psychiatry.

[33]  David A Lewis,et al.  Catching Up on Schizophrenia Natural History and Neurobiology , 2000, Neuron.

[34]  O. Ramírez,et al.  Effects of chronic risperidone on central noradrenergic transmission. , 2000, European journal of pharmacology.

[35]  P. Goldman-Rakic,et al.  D1 receptors in prefrontal cells and circuits , 2000, Brain Research Reviews.

[36]  G. Aghajanian,et al.  Molecular control of locus coeruleus neurotransmission , 1999, Biological Psychiatry.

[37]  E. Abercrombie,et al.  Relationship between locus coeruleus discharge rates and rates of norepinephrine release within neocortex as assessed by in vivo microdialysis , 1999, Neuroscience.

[38]  Holly Moore,et al.  The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia , 1999, Biological Psychiatry.

[39]  Anthony A. Grace,et al.  Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs , 1997, Trends in Neurosciences.

[40]  G. Aston-Jones,et al.  Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus , 1996, Brain Research.

[41]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[42]  Rex Y. Wang,et al.  Locus coeruleus norepinephrine-containing neurons: effects produced by acute and subchronic treatment with antipsychotic drugs and amphetamine , 1986, Brain Research.

[43]  Clinical Implications. , 2017, Hypertension.

[44]  Cameron S Carter,et al.  Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning , 2011, Neuropsychopharmacology.

[45]  M. Laruelle,et al.  Neurobiology of dopamine in schizophrenia. , 2007, International review of neurobiology.

[46]  S. Sesack,et al.  Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. , 2003, Annals of the New York Academy of Sciences.

[47]  A Carlsson,et al.  Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. , 2001, Annual review of pharmacology and toxicology.